TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3286673
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin delivery (0.8 mU kg‐1 min‐1 for normal men; 0.15 mU kg‐1 min‐1 for type 1 diabetic patients)
Study: 3286673
Drug: Intermittent insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent insulin delivery (0.97 mU kg‐1 min‐1 for 2 min, followed by 11 min no infusion for type 1 diabetic patients)
Study: 23642377
Drug: Bevacizumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (monthly or as-needed)
Study: 19309712
Drug: Primary PCI
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary PCI with triple antiplatelet therapy
Study: 16681559
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin inhalation powder (HIIP)
Study: 16681559
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) insulin
Study: 9430375
Drug: Simvastatin 160
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 160 mg/day (group 1)
Study: 3307620
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate lozenges (10 mg), average utilization 5.4 days at an average dose of six lozenges daily
Study: 3307620
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc acetate lozenges (10 mg)
Study: 23295793
Drug: Toremifene citrate
Normalized name: Toremifene Citrate
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene citrate 20 mg
Study: 21426748
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy group (50 patients)
Study: 21426748
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy group (50 patients) with MLA < 4.0 mm(2)
Study: 17962712
Drug: Echinacea (ECH)
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea (ECH) 8000 mg/d (5 x 400 mg x 4 times/d for 28 days)
Study: 14724051
Drug: 5-Hydroxy-L-tryptophan (5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Hydroxy-L-tryptophan (5-HTP) 3-200 mg/kg ip
Study: 14724051
Drug: 5-Hydroxy-L-tryptophan (5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Hydroxy-L-tryptophan (5-HTP)
Study: 14724051
Drug: 5-Hydroxy-L-tryptophan (5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Hydroxy-L-tryptophan (5-HTP) with L-valine
Study: 11420028
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate (FP) 400 micrograms/day administered into each nostril twice a day for 45 days
Study: 2524362
Drug: Dihydroxyprogesterone acetophenide
Normalized name: acetophenone
DrugBank: Acetophenone (DB04619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroxyprogesterone acetophenide 150 mg and estradiol enanthate 10 mg (DHPA/E2-EN)
Study: 2524362
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg (MPA/E2-C)
Study: 24708857
Drug: SCAP method
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCAP method (dose reduction of antipsychotics)
Study: 15680855
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution
Study: 17667483
Drug: Individual trauma-focused
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual trauma-focused cognitive-behavioral therapy (CBT) for 10 weeks
Study: 17667483
Drug: Individual trauma-focused
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual trauma-focused cognitive-behavioral therapy (CBT)
Study: 12548586
Drug: Bisphosphonates as
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates as adjuvant therapy
Study: 1906120
Drug: Nadolol, 40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol, 40-160 mg/day
Study: 1906120
Drug: Anaprilin, 80-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaprilin, 80-240 mg/day
Study: 30951837
Drug: Peer coach-led
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer coach-led pain self-management intervention (6 months, patient-peer coach pairs talk twice per month)
Study: 27838341
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behaviour therapy (CBT) for 9 weeks
Study: 2189452
Drug: Lidocaine 2
Normalized name: lidocaine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2 mg/kg
Study: 22588946
Drug: Procaine hydrochloride
Normalized name: Procaine Hydrochloride
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procaine hydrochloride 5 mg/kg
Study: 19247636
Drug: Alcohol 0.4
Normalized name: isopropyl alcohol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.4 g/kg
Study: 12324991
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg)
Study: 7538959
Drug: HES (Hydroxy‐Ethyl‐Starch)
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES (Hydroxy‐Ethyl‐Starch) treatment
Study: 2166934
Drug: Azithromycin (5-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5-day therapy)
Study: 2166934
Drug: Josamycin (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin (10-day therapy)
Study: 7016627
Drug: Pyritinol 200
Normalized name: pyritinol
DrugBank: Pyritinol (DB13084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol 200 mg three times a day for a period of 6 weeks
Study: 17957793
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg/day
Study: 18389188
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/day plus CPA/EE (2 mg CPA/35 microg EE)
Study: 16856548
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg x kg(‐1) of rocuronium with sevoflurane
Study: 16856548
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg x kg(‐1) of rocuronium with propofol
Study: 16856548
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg x kg(‐1) of rocuronium with sevoflurane
Study: 16856548
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg x kg(‐1) of rocuronium with propofol
Study: 10902748
Drug: CRP >=25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP >=25 mg/liter
Study: 3159318
Drug: Intradermal skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal skin testing with tubocurarine and atracurium (diluted 1 in 1,000)
Study: 29642282
Drug: N6022 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: N6022 (5 mg)
Study: 19240085
Drug: Olanzapine (OLZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (OLZ, 10-20 mg/day)
Study: 10756746
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (group B), given in one dose
Study: 3731679
Drug: amiflamine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amiflamine, 5 mg bid (n = 8)
Study: 3731679
Drug: placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 1 capsule twice a day (n = 4)
Study: 3731679
Drug: oral tyramine
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tyramine (400 mg)
Study: 27338467
Drug: Dietary counselling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counselling to increase fruit intake (+1 serving/day; 150 g/day)
Study: 27338467
Drug: Dietary counselling
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary counselling to increase dairy intake (+1 serving/day; 200-250 g/day)
Study: 25006720
Drug: Hypothermia (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia (rectal temperature of 33 to 34°C for 72 hours within 6 hours after birth)
Study: 15301918
Drug: Butorphanol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0, 0.5, 1, and 2 mg/70 kg)
Study: 15301918
Drug: Cold-water stimulus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-water stimulus (2 degrees C) during butorphanol administration
Study: 12174334
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg daily for 21 days)
Study: 10503166
Drug: Lentinan 5
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan 5 mg i.v. once a week for eight weeks
Study: 10503166
Drug: Lentinan 10
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan 10 mg i.v. once a week for eight weeks
Study: 10503166
Drug: Lentinan 5
Normalized name: lentinan
DrugBank: Lentinan (DB13480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentinan 5 mg i.v. twice a week for 12 weeks
Study: 7521940
Drug: Nimodipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (1 mg-2 mg intravenously)
Study: 7521940
Drug: Dextran 40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40,000 (standard therapy)
Study: 2519936
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (1.5 mg/kg)
Study: 31014423
Drug: calsurf treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: calsurf treatment + conventional treatment
Study: 28244416
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m2) plus gemcitabine (50‐125 mg/m2) (C/G)
Study: 25542343
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy adapted for health anxiety (delivered by nurses)
Study: 23984312
Drug: Bromocriptine (BEC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BEC) 2.5 mg, initially 1 tablet with subsequent increase to three times a day
Study: 23984312
Drug: Placebo (PBO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO), initially 1 tablet with subsequent increase to three times a day
Study: 21869699
Drug: Aripiprazole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2.5 mg/d plus sertraline 50 mg/d
Study: 21869699
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus sertraline 50 mg/d
Study: 15194981
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with loading dose
Study: 15194981
Drug: Clopidogrel without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel without loading dose
Study: 15381441
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy with a cognitive restructuring component focused on body image (CBT-C)
Study: 8378900
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Curosurf (200 mg/kg initial dose, up to five doses)
Study: 8378900
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Curosurf (100 mg/kg initial dose, up to three doses)
Study: 29335791
Drug: Dexamethasone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (30 mg total dose, perioperatively)
Study: 25128485
Drug: Antenatal self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal self-administration of unfractionated heparin (UFH) 7500 IU twice-daily
Study: 21436923
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy Management (MTM) services provided by third-year pharmacy students
Study: 18841288
Drug: Tirofiban (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (bolus of 10 microg/kg body weight followed by continued infusion of 0.15 microg/kg body weight per minute)
Study: 17126650
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg 2 times daily)
Study: 12792289
Drug: Isoflavones (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (110 mg total per day)
Study: 10320160
Drug: Aggressive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive insulin therapy (AIT)
Study: 1838916
Drug: Cilazapril 10
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 10 mg + Hydrochlorothiazide
Study: 28213566
Drug: Mavrilimumab 150
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 150 mg
Study: 23234647
Drug: Mavrilimumab 100
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 100 mg
Study: 23234647
Drug: Mavrilimumab 30
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 30 mg
Study: 25643304
Drug: Energy-dense, protein-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense, protein-rich oral formula enriched with arginine, zinc, and antioxidants (400 mL/d)
Study: 24004451
Drug: Yukmijihwang-tang administered
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yukmijihwang-tang administered for 8 weeks
Study: 21880799
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal E(2) (0.0375 mg)
Study: 21880799
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral E(2) (2.0 mg)
Study: 21880799
Drug: High-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose transdermal E(2) (0.075 mg)
Study: 16837886
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2)
Study: 21880799
Drug: Oral E(2)
Normalized name: Aquasol E Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E(2) (low or high dose)
Study: 10155734
Drug: Immunosuppressive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drugs only (Control)
Study: 2521184
Drug: GR38032F 0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR38032F 0.18 mg/kg every 2 hours (trial 1)
Study: 6127970
Drug: Intramuscular dihydrocodeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dihydrocodeine
Study: 29708766
Drug: Combined MTrP
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined MTrP therapy and stretching plus suboccipital soft tissue inhibition
Study: 29708766
Drug: Combined MTrP
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined MTrP therapy and stretching (control group)
Study: 24874285
Drug: Treatment change
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment change (start or change of adjuvant endocrine agent)
Study: 11515711
Drug: Clarithromycin formulation
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin formulation 1 (250 mg)
Study: 8113479
Drug: Time-limited psychodynamically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-limited psychodynamically oriented treatments (12 sessions)
Study: 8113479
Drug: Time-unlimited psychodynamically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-unlimited psychodynamically oriented treatments
Study: 6122188
Drug: Diazepam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (7.5 mg)
Study: 26253730
Drug: Prandial Technosphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial Technosphere inhaled insulin (TI)
Study: 26253730
Drug: Prandial Technosphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial Technosphere inhaled placebo (TP)
Study: 11285152
Drug: 4-day parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day parenteral beta-lactam therapy
Study: 11285152
Drug: 7-day parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day parenteral beta-lactam therapy
Study: 9483391
Drug: Caffeine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (loading dose 10 mg/kg followed by 5 mg/kg/day)
Study: 8148229
Drug: ICI 192605
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 192605 (100 mg)
Study: 3162905
Drug: Enoxacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (single dose or three divided doses)
Study: 19369445
Drug: Clinician-collected rectal
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-collected rectal swab specimens
Study: 17462550
Drug: SVLPD (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVLPD (0.3 g/kg/d of vegetable proteins and ketoanalogues, 1 capsule for every 5 kg of ideal body weight per day)
Study: 17462550
Drug: Conventional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low mixed protein diet (0.6 g/kg/d)
Study: 26283139
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous alteplase (0.9 mg/kg body weight)
Study: 19627532
Drug: US-guided ilioinguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided ilioinguinal nerve block with 0.1 ml x kg(‐1) of 0.25% bupivacaine with 1 : 200,000 epinephrine
Study: 19627532
Drug: Single-shot caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot caudal block with 0.7 ml x kg(‐1) of 0.125% bupivacaine with 1 : 200,000 epinephrine
Study: 17101847
Drug: RB006 (anticoagulant)
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: RB006 (anticoagulant)
Study: 15561322
Drug: Telmisartan 40-80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40-80 mg once daily for 1 year
Study: 1882895
Drug: Sucralfate tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate tablets, 4 g/day for 8 weeks
Study: 29110518
Drug: Age-appropriate preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-appropriate preparation for children undergoing RT
Study: 17245777
Drug: Individual home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual home therapy (Group A)
Study: 15090951
Drug: Alcoholic povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic povidone-iodine solution protocol
Study: 15090951
Drug: Aqueous 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous 10% povidone-iodine solution protocol
Study: 11213982
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg orally (prolonged-release) and 50 mg intramuscularly
Study: 11783221
Drug: Huodan Tablet
Normalized name: Menthol 30 mg TOPICAL PATCH [Alhua Huogan Pain Relieving Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huodan Tablet
Study: 2663152
Drug: Trazodone or
Normalized name: trazodone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone or another antidepressant
Study: 28333187
Drug: Eldelumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldelumab (both doses)
Study: 23621698
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with infliximab 5 mg kg(‐1) every 8 weeks
Study: 23621698
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (no infliximab until > 50% loss of PASI improvement)
Study: 21252632
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS reminders
Study: 15055982
Drug: 19% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19% sodium percarbonate gel
Study: 9197167
Drug: Metronidazole 800
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 800 mg tid for 10 days combined with needle aspiration (group A)
Study: 9197167
Drug: Metronidazole therapy
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole therapy alone (group B)
Study: 16600508
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg)
Study: 21946190
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (5-pertussis-component)
Study: 27142328
Drug: No vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccine (control group)
Study: 18289869
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive therapy (CIST)
Study: 2857265
Drug: Experimental diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental diet high in polyunsaturated fat and low in saturated fat with daily supplement of 1.8 g eicosapentaenoic acid
Study: 30854818
Drug: XPF 3
Normalized name: Xylometazoline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: XPF 3 mL of 3% NaOCl for 1 min (group A)
Study: 30854818
Drug: PUI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUI of 3 mL of 3% NaOCl for 1 min (group C)
Study: 30854818
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 3% NaOCl for 1 min by using a syringe and a 30 G side‐vented needle (group E)
Study: 30854818
Drug: PUI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUI of 3 mL of 3% NaOCl for 1 min, followed by 4 mL of 17% EDTA for 1 min (group D)
Study: 26785826
Drug: Deferiprone (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (dosage not specified)